市場調查報告書
商品編碼
1471096
精準醫療市場:依技術、應用程式、最終用戶、配置- 2024-2030 年全球預測Precision Medicine Market by Technology (Big Data Analytics, Bioinformatics, Companion Diagnostics), Application (CNS, Immunology, Oncology), End-User, Deployment - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年精準醫療市場規模為681.2億美元,預計2024年將達757億美元,2030年將達到1,434.3億美元,複合年成長率為11.22%。
精準醫療是指考慮患者遺傳、環境和生活方式的差異,並制定疾病預防和治療方案的策略。這個概念可以作為癌症、心臟病、囊腫纖維化、糖尿病等的有效預防方法。精準醫學用於預測疾病易感性、改善疾病檢測並提供量身定做的疾病預防策略。政府正迅速加強改善精準醫療領域的研發活動,同時增加低收入者獲得醫療保健治療選擇的機會。製藥、軟體和生物資訊公司共同努力表徵基因,擴大了藥物發現。然而,精準醫學治療的報銷以及缺乏標準化報銷代碼和定義阻礙了患者招募和研發工作。此外,FDA 複雜的藥物治療核准流程和隨後的商業化挑戰也是主要障礙。然而,由於政府和監管機構努力確保基因定序和次世代定序的準確性,監管合規性正在改善。此外,人工智慧、機器學習和雲端基礎的解決方案的採用使研究人員能夠使用電子健康記錄中的複雜資料來檢測早期疾病,例如阿茲海默症和失智症。
主要市場統計 | |
---|---|
基準年[2023] | 681.2億美元 |
預測年份 [2024] | 757億美元 |
預測年份 [2030] | 1434.3億美元 |
複合年成長率(%) | 11.22% |
科技巨量資料分析推進精準醫療領域
巨量資料分析和生物資訊技術利用實驗和電子健康記錄中的分子、臨床和數位資料來開發精準醫學和治療方法。伴同性診斷是指用於檢測更有可能對精準醫學治療技術做出反應的患者的特定基因突變或生物標記的測試。精準醫學利用基因序列測定和次世代定序儀對多個基因進行定序並識別與疾病相關的基因突變,幫助患者獲得正確的治療方法。
應用範例:利用精準醫療進行個人化癌症/腫瘤治療
在中樞神經系統疾病的治療中使用精準醫學可以促進全面的基因評估、生物標記的識別以及基於患者遺傳學的治療方法修改。透過評估與發炎性腸道疾病(IBD)和全身性紅斑性狼瘡免疫性疾病相關的生物標記物,可以透過精準醫療有效地針對這些疾病進行治療。大腸直腸癌、胃癌和肺癌可以透過個人化醫療來治療,個人化醫療可根據特定組織、基因突變和與每個癌症病例相關的因素提供個人化治療方法。在呼吸系統疾病中,精準醫學用於評估患者是否接受支氣管鏡和外科手術干預,例如支氣管鏡肺減容術和肺減容術。
最終用戶的研發投資以及生技和診斷公司為推動精準醫療領域所做的努力
主要生物技術和診斷公司從事與個人化癌症治療和疫苗開發以及藥物發現相關的研發活動。不斷發展的科學技術進步正在推動精準醫學在實驗室和醫學中的使用,以進行個人化疾病診斷以及隨後為患者開發適當的治療方法。領先的研究中心和政府機構致力於進行研究合作,以揭示心臟病、糖尿病、肥胖症和其他與年齡相關的疾病等常見疾病的原因。
部署:整合人工智慧和雲端解決方案,提高精準醫療服務的有效性和開發速度
雲端運算和人工智慧的整合創建了基因組雲端解決方案,使臨床醫生即使在偏遠地區也能分析大型患者資料集。透過雲端平台部署精準醫療解決方案,提高分析效率。使用雲端解決方案提前檢測阿茲海默症和失智症疾病正在引起人們的注意。本地精準醫療利用 NGS 分析和體學實驗產生並儲存在機構資料庫中的資料。
區域洞察
在美洲,人們對將人工智慧和機器學習整合到精準醫療中以治療和管理癌症和腫瘤的興趣日益濃厚。美洲政府的措施正在鼓勵臨床醫生和醫生採用精準醫學進行治療。墨西哥和哥倫比亞正致力於分析其公民的整個基因組成,以幫助醫療和研究相關人員做出更準確的醫療決策。在亞太地區,包括印度和中國在內的新興經濟體正在增加對基因療法研究和開發微型機器人等產品的投資以協助管理。此外,這些國家越來越多的癌症診所和醫院正在使用精準醫療來指南病患的診斷和治療。日本政府旨在促進醫療記錄的協作,包括醫學基因組檢測資料和個人健康記錄(PHR),這可以改善精準醫療和藥物開發。在英國、德國和瑞士等歐洲國家,強大的研究機構和學術機構對新穎研究的關注正在推動個人化治療方法和藥物的發展。該地區正在鞏固其在生命科學領域的地位,大型製藥企業和生物技術公司提供精準醫療解決方案。
FPNV定位矩陣
FPNV定位矩陣對於評估精準醫療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對精準醫療市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.精準醫療市場規模及預測是多少?
2.在精準醫療市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.精準醫療市場的技術趨勢和法規結構是什麼?
4.精準醫療市場主要廠商的市場佔有率為何?
5. 進入精準醫療市場的合適型態或策略手段是什麼?
[196 Pages Report] The Precision Medicine Market size was estimated at USD 68.12 billion in 2023 and expected to reach USD 75.70 billion in 2024, at a CAGR 11.22% to reach USD 143.43 billion by 2030.
Precision medicine refers to the strategy of tailoring disease prevention and treatment solutions by considering the differences in patient's genetics, environments, and lifestyles. This concept can be utilized as an effective prevention technique for cancers, heart diseases, cystic fibrosis, and diabetes. Precision medicine is used to predict disease susceptibility, improve disease detection, and offer customized disease-prevention strategies. Government efforts to improve research and development activities in the precision medicine sector and simultaneously improve the accessibility of healthcare treatment options for lower-income individuals are increasing rapidly. Joint efforts between pharmaceutical, software, and bioinformatics companies to characterize the genes have expanded drug discovery. However, the lack of reimbursement for precision medicine-based treatment and standardized reimbursement codes and definitions hampers patient adoption and R&D activities. Additionally, the complicated FDA pharmacotherapy approval process and subsequent commercialization challenges of the product pose significant hurdles. However, efforts by government and regulatory agencies to ensure the accuracy of gene sequencing and next-generation sequencing have improved compliance with regulations. Additionally, the adoption of AI, ML, and cloud-based solutions allows researchers to use complex data from electronic health records to detect early-onset diseases, including Alzheimer's and dementia.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 68.12 billion |
Estimated Year [2024] | USD 75.70 billion |
Forecast Year [2030] | USD 143.43 billion |
CAGR (%) | 11.22% |
Technology: Big data analytics is advancing the field of precision medicine
Big data analytics and bioinformatics technologies utilize molecular, clinical, and digital data derived from experimentation and electronic health records for the development of precision medicines and therapies. Companion diagnostics refer to tests used to detect specific genetic mutations and biomarkers in patients who have a higher probability of responding to precision medicine treatment techniques. Gene sequencing and Next-generation sequencing are utilized in precision medicine to sequence multiple genes and identify disease-associated gene mutations to facilitate matching of patients to appropriate therapies.
Application: Personalized cancer and oncology care using precision medicine
Precision medicine for the treatment of CNS disorders can be used to facilitate comprehensive genetic assessment, identifying biomarkers, and modification of treatments according to the patient's genetics. Immune disorders, including Inflammatory Bowel Disease (IBD) and Systemic Lupus Erythematosus, can be effectively targeted by precision medicine by evaluation of biomarkers implicated in these diseases. Colorectal cancer, stomach cancer, and lung cancer can be tackled by utilization of a personalized medicine regime that offers individualized treatment options tailored to specific tissues, genetic mutations, and factors relevant to each case of cancer. For respiratory diseases, precision medicine has been used for the assessment of patients for bronchoscopic or surgical interventions such as bronchoscopic lung volume reduction and lung volume reduction surgery.
End-user: Efforts by biotechnology and diagnostic companies to invest in R&D and advance the field of precision medicine
Major biotechnology and diagnostic companies are developing personalized cancer therapeutics and personalized vaccines and are involved in R&D activities related to drug discovery. Evolving scientific and technological advancements have propelled the utilization of precision medicine in laboratories and pharmaceuticals for personalized disease diagnosis and subsequent development of appropriate treatment regimes for the patient. Major research centers and government institutions are focusing on developing collaborative research to understand the causes of common diseases, including heart disease, diabetes, obesity, and other aging-related morbidities.
Deployment: Integration of AI and cloud solutions to improve efficacy and speed of development of precision medicine services
Cloud computing and the integration of AI have led to the generation of genomic cloud solutions that allow clinicians to analyze larger patient datasets, even in remote settings. Deployment of precision medicine solutions through on-cloud platforms improves the analysis efficiency. The utilization of cloud solutions for the detection of diseases such as Alzheimer's and dementia in advance is gaining attention. On-premise deployment of precision medicine involves the utilization of data generated during NGS analysis and omics experiments and stored in institutional databases.
Regional Insights
Countries in the Americas are increasing the focus on the integration of AI and ML in precision medicine for the treatment and management of cancers and tumors. Government efforts in the Americas has propelled the deployment of precision medicine by clinicians and physicians for treatment purposes. Mexico and Colombia are exerting efforts to analyze the entire genetic constitution of the citizens to better equip medical and research personnel with medical decision-making. In the APAC region, emerging economies, including India and China, are increasing investment in gene therapy research and developing products such as microbots that aim to support precision medicine delivery. These countries are also experiencing a rising number of cancer care clinics and hospitals that utilize precision medicine to guide patient diagnosis and treatment. The Japanese government aims to promote the linkage of medical records, including medical genomic testing data and personal health records (PHRs), which can improve the development of precision medicines and drugs. In the European nations of UK, Germany, and Switzerland, the presence of robust research institutions and focus of academic institutions on novel research is responsible for driving the development of personalized treatment regimes and medicines. The provision of precision medicine solutions by major pharmaceutical and biotechnological companies located in European nations has allowed the region to solidify its position in the life sciences sector.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Precision Medicine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Precision Medicine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AccessDX Holdings, Adaptive Biotechnologies Corporation, Biocrates Life Sciences AG, bioMerieux SA, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Foundation Medicine, Inc., Guardant Health, Inc., healthOme, Illumina, Inc., Intomics by ZS Associates, Inc., Invitae Corporation., Laboratory Corporation of America Holdings, Medtronic PLC, Natera Inc., Novartis AG, Pfizer Inc., Precision Medicine Group, LLC, QIAGEN GmbH, Quest Diagnostics Incorporated, Strata Oncology, Inc., Syapse, Inc., Tempus Labs, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Precision Medicine Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Precision Medicine Market?
3. What are the technology trends and regulatory frameworks in the Precision Medicine Market?
4. What is the market share of the leading vendors in the Precision Medicine Market?
5. Which modes and strategic moves are suitable for entering the Precision Medicine Market?